ADDITIONAL INDUCTION ELIGIBILITY CRITERIA:Xx_NEWLINE_xXPatients treated with prior surgery are eligible for this study if they otherwise meet eligibility criteriaXx_NEWLINE_xXPatients are eligible >= 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are metXx_NEWLINE_xXELIGIBILITY CRITERIA FOR ENROLLMENT ON THE RE-TREATMENT STUDYXx_NEWLINE_xXINTRA-OPERATIVE REGISTRATION/RANDOMIZATION CRITERIAXx_NEWLINE_xXPOST-OPERATIVE REGISTRATION/RANDOMIZATION CRITERIAXx_NEWLINE_xXNote: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteriaXx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patients randomized to Arm 1 may opt to switch to the 3-drug regimen following disease progression; these patients must be re-registered to the study and meet the eligibility criteria belowXx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Platelet count >= 50 x 10^9/LXx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): AST and ALT < 2.5 x upper limits of normal (ULN)Xx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Note: G-CSF and platelet transfusions cannot be used to increase counts to meet eligibility criteriaXx_NEWLINE_xXINDUCTION ELIGIBILITY CRITERIA-STEP 1Xx_NEWLINE_xXPOST-INDUCTION THERAPY ELIGIBILITY CRITERIA (PRIOR TO INTENSIFICATION-STEP 2)Xx_NEWLINE_xXPatients should meet the eligibility criteria for RANDOMIZATION TO BLINATUMOMAB OR NO BLINATUMOMAB-STEP 3Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR SCREENING AND MOLECULAR PROFILING (STEP 0)Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): ECOG performance status 0 or 1 within 2 weeks prior to randomizationXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Patients must have completed treatment with any investigational agent >= 30 days prior to randomization for protocol therapy, if applicableXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Patients must be randomized within 24 weeks from surgeryXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Platelets > 100,000 mm^3Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Aspartate aminotransferase (AST, SGOT) =< 2.5 x ULNXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Alanine aminotransferase (ALT, SGPT) =< 2.5 x ULNXx_NEWLINE_xXSTUDY SITE ELIGIBILITY:Xx_NEWLINE_xXREGISTRATION ELIGIBILITY CRITERIA:Xx_NEWLINE_xXREGISTRATION ELIGIBILITY CRITERIA (STEP 1)Xx_NEWLINE_xXELIGIBILITY CRITERIA (STEP 1)Xx_NEWLINE_xXREGISTRATION/RANDOMIZATION ELIGIBILITY CRITERIAXx_NEWLINE_xXELIGIBILITY CRITERIA FOR PREREGISTRATION (STEP 0):Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1):Xx_NEWLINE_xXREGISTRATION ELIGIBILITY CRITERIAXx_NEWLINE_xXINCLUSION CRITERIA FOR SCREENING (STEP 0 - PREREGISTRATION)Xx_NEWLINE_xXINCLUSION CRITERIA FOR TREATMENT ASSIGNMENT (STEP 1)Xx_NEWLINE_xXPatients must have met eligibility criteria for the screening stepXx_NEWLINE_xXSite must verify that there is no known change in the step 1 eligibility since initial registrationXx_NEWLINE_xXREGISTRATION ELIGIBILITY CRITERIA (STEP 1)Xx_NEWLINE_xXRANDOMIZATION ELIGIBILITY CRITERIA (STEP 2)Xx_NEWLINE_xX